Immunizing definition

Immunizing the insurance company's wealth against substantial shifts in interest rates therefore remain a major objective. Since MLIG insurance products are "customized" liabilities, the Investment Management group will periodically meet with the actuaries to assess the key risk attributes of the liabilities (i.e. duration, convexity) of the MLIG products, the underlying cash flows of the liabilities and the sensitivity of the liability market values to changes in interest rates (both parallel and non-parallel yield curve shifts). These liability risk measures will be updated monthly, reflecting the influx of new business and the aging of old policies. Such information will be provided to the appropriate investment managers by the MLIG Investment Management Group on a monthly basis. The risk parameters (i.e. duration and convexity) for the assets will be established in accordance with the same measures for liabilities, so that under normal conditions changes in interest rates will have offsetting impact on the firm's assets and liabilities. Portfolio managers, however, may be allowed to deviate from the risk guidelines, depending on their interest rate outlook and yield curve perspective. Deviations beyond +/- 1 of the effective duration, however, require the approval of the Investment Committee and the involvement of the Investment Management group in adequately hedging the interest rate risk. The credit risk is to be controlled by adhering to the sector exposure in accordance with the guidelines established for various asset classes. The portfolio managers, however, may deviate from those norms based on their relative value perspective, subject to maximum limits imposed by the following portfolio guidelines. Federal, State and other local laws that govern insurance companies stipulate "eligible investments" for insurance companies. Not withstanding anything listed below, those laws take precedence in what may be termed as viable investment alternatives for the insurance company assets: In general, portfolio managers can invest in following assets subject to limitations listed in following paragraphs: - Short-term instruments including Certificates of Deposits, Commercial Paper, Bankers Acceptances, Medium-Term Notes, Euro CDs, Treasury Bills, Repurchase and Reverse Repurchase agreements - U.S. Treasury and Agency debt obligations - Mortgage-backed securities (including collateralized mortgage obligations) and Asset-Backed Securities of any federal agency or private...
Sample 1
Immunizing the insurance company's wealth against substantial shifts in interest rates therefore remains a major objective. Since MLIG insurance products are "customized" liabilities, the Investment Management group will periodically meet with the actuaries to assess the key risk attributes of the liabilities (i.e. duration, convexity) of the MLIG products, the underlying cash flows of the liabilities and the sensitivity of the liability market values to changes in interest rates (both parallel and non-parallel yield curve shifts). These liability risk measures will be updated monthly, reflecting the influx of new business and the aging of old policies. Such information will be provided to the appropriate investment managers by the MLIG Investment Management Group on a monthly basis. The risk parameters (i.e. duration and convexity) for the assets will be established in accordance with the same measures for liabilities, so that under normal conditions changes in interest rates will have offsetting impact on the firm's assets and liabilities. Portfolio managers, however, may be allowed to deviate from the risk guidelines, depending on their interest rate outlook and yield curve perspective. Deviations beyond +/- The credit risk is to be controlled by adhering to the sector exposure in accordance with the guidelines established for various asset classes. The portfolio managers, however, may deviate from those norms based on their relative value perspective, subject to maximum limits imposed by the following portfolio guidelines.
Sample 1
Immunizing the insurance company's wealth against substantial shifts in interest rates therefore remain a major objective. Since MLIG insurance products are "customized" liabilities, the Investment Management group will periodically meet with the actuaries to assess the key risk attributes of the liabilities (i.e. duration, convexity) of the MLIG products, the underlying cash flows of the liabilities and the sensitivity of the liability market values to changes in interest rates (both parallel and non-parallel yield curve shifts). These liability risk measures will be updated monthly, reflecting the influx of new business and the aging of old policies. Such information will be provided to the appropriate investment managers by the MLIG Investment Management Group on a monthly basis. The risk parameters (i.e. duration and convexity) for the assets will be established in accordance with the same measures for liabilities, so that under normal conditions changes in interest rates will have offsetting impact on the firm's assets and liabilities. Portfolio managers, however, may be allowed to deviate from the risk guidelines, depending on their interest rate outlook and yield curve perspective. Deviations beyond +/-1 of the effective duration, however, require the approval of the Investment Committee and the involvement of the Investment Management group in adequately hedging the interest rata risk. Credit risk is to be controlled by adhering to the sector exposure in accordance with the guidelines established for various asset classes. The portfolio managers, however, may deviate from those norms based on their relative value perspective, subject to maximum limits imposed by the following portfolio guidelines.
Sample 1

Examples of Immunizing in a sentence

  • Immunizing agents, biological sera, blood, blood products or blood plasma.

  • An Immunizing Pharmacist shall document the annual review with the Physician of the Written Protocol as required in this Rule.

  • An Immunizing Pharmacist shall administer only those vaccines or immunizations permitted by G.S. 90-85.15B and shall do so subject to all requirements of that statute and this Rule.

  • The Physician and the Immunizing Pharmacist shall review the Written Protocol at least annually and revise it if necessary.

  • The Immunizing Pharmacist shall maintain written policies and procedures for handling and disposal of used or contaminated equipment and supplies.

  • After administering vaccines at a location other than a pharmacy, the Immunizing Pharmacist shall return all unused prescription medications to the pharmacy or Physician responsible for the drugs.

  • The Immunizing Pharmacist or Pharmacy Intern must ensure that the patient or legal representative has the opportunity to read, or to have read to him or her, the information provided and to have any questions answered prior to administration of the vaccine.

  • An Immunizing Pharmacist who, because of physical disability, is unable to obtain a current provider level CPR certification pursuant to G.S. 90-85.3(i1)(1), may administer vaccines in the presence of a pharmacy technician or pharmacist who holds a current provider level CPR certification.

  • With each dose of vaccine, either the Immunizing Pharmacist or a Pharmacy Intern shall give the most current vaccine information regarding the purpose, risks, benefits, and contraindications of the vaccine to the patient or legal representative.

  • An Immunizing Pharmacist shall report adverse events associated with administration of a vaccine to either the prescriber, when administering a vaccine pursuant to G.S. 90-85.15B(a), or the patient's primary care provider, if the patient identifies one, when administering a vaccine pursuant to G.S. 90-85.15B(b).

Related to Immunizing

  • Immunization means the act of inducing antibody formation, thus leading to immunity.

  • HIV means human immunodeficiency virus.

  • Biological agent shall mean any pathogenic (disease producing) micro-organism(s) and/or biologically produced toxin(s) (including genetically modified organisms and chemically synthesized toxins) which cause illness and/or death in humans, animals or plants.

  • Diagnosis means the definition of the nature of the Client's disorder. When formulating the Diagnosis of Client, CONTRACTOR shall use the diagnostic codes and axes as specified in the most current edition of the DSM published by the American Psychiatric Association. DSM diagnoses will be recorded on all IRIS documents, as appropriate.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Patients means both Public Patients and the Private Patients (referred by private doctors/private hospitals);

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Biological diversity means the variability among living organisms from all sources including, inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes of which they are part; this includes diversity within species, between species and of ecosystems.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Acute toxicity means concurrent and delayed adverse effects that result from an acute exposure and occur within any short observation period, which begins when the exposure begins, may extend beyond the exposure period, and usually does not constitute a substantial portion of the life span of the organism.

  • animals means animals as defined in the Terrestrial Animal Health Code or the Aquatic Animal Health Code of the World Organisation for Animal Health (OIE), respectively;

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Anesthesiologist means a physician granted clinical privileges to administer anesthesia.

  • Prosthesis means an artificial substitute for a missing body part.

  • Progeny means unmodified descendant from the Material, such as virus from virus, cell from cell, or organism from organism.

  • Embryo/fetus means the developing human organism from conception until the time of birth.

  • Antipsychotic medications means that class of drugs

  • Animal means any nonhuman animate being endowed with the power of voluntary action.

  • Psychotherapy or "Therapy" means a goal directed process using generally accepted clinical approaches provided face-to-face by a qualified service provider with consumers in individual, group or family settings to promote positive emotional or behavioral change.

  • Brachytherapy source means a radioactive source or a manufacturer-assembled source train or a combination of these sources that is designed to deliver a therapeutic dose within a distance of a few centimeters.

  • Clinical means having a significant relationship, whether real or potential, direct or indirect, to the actual rendering or outcome of dental care, the practice of dentistry, or the quality of dental care being rendered to a patient;

  • Clinician means a State licensed physician, except if the

  • COVID-19 symptoms means fever of 100.4 degrees Fahrenheit or higher, chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea, unless a licensed health care professional determines the person’s symptoms were caused by a known condition other than COVID-19.

  • Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described on Exhibit A, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). These Biological Materials shall be listed on Exhibit A, which will be periodically amended to include any additional Biological Materials that Medical School may furnish to Company.

  • Investigational Medicinal Product means the study drug or control material as defined in the Protocol.

  • Biological Material means any material containing genetic information and capable of reproducing itself or being reproduced in a biological system;